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bladder base and urethral radiation injuries. Our ability to 
predict these injuries prior to radiotherapy remains limited, 
however. For example, rectal dose volumes are a widely used 
planning tool, but published relationships between irradiated 
volumes and outcomes are inconsistent. 
The presentation is a strictly clinical overview of the factors 
that contribute to ano-rectal radiation injuries and outlines 
recent progress in their management. Symptomatology 
resulting from rarely cited injuries, such as to the per-rectal 
fat and the pelvic floor musculature, are also discussed. 
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Since the last 10 years 3D image-guided brachytherapy using 
CT, MRI, and/or ultrasound (US) has been introduced into 
clinical practice worldwide enabling conformation of the 
dose distribution to the target volume and avoidance of high 
dose to organs at risk (OAR). To be able to optimise the dose 
distribution in brachytherapy both the anatomy (target 
volume/OAR) and the applicator(s) should be correctly 
localised in the images. If the image modality does not 
enables both of these criteria the dose delivered the patient 
may be calculated incorrectly. Another important aspect is 
that the images should reflect the true situation at the time 
of the treatment. Due to the large dose gradient in 
brachytherapy, even small changes in the position of the 
applicator and/or anatomical structures may lead to 
discrepancies between planned and delivered dose. Usually, 
this is achieved with as short time as possible between 
imaging and treatment delivery. 
The optimal image modality to use is depending on the site 
to be treated as well as the geometry and the material of the 
applicator. For cervical cancer MR imaging is the optimal 
modality to discriminate soft tissue and tumour. Concepts for 
image guided cervical brachytherapy have been developed by 
GEC-ESTRO and T2 weighted MR imaging is the preferred 
modality. In an interobserver study the mean inter-
delineation distance of around 4 mm were found for the high 
risk CTV (HR CTV). The impact of these uncertainties for D90 
and D100 (dose to 90% and 100% of the volume) were 10% and 
19%, respectively.  
Post-implant dosimetry after permanent prostate seed 
implantation is usually based on CT imaging. However, MR 
imaging has superior soft tissue contrast and is some times 
used nowadays. In an interobserver study the dosimetric 
consequence of the delineation uncertainty was estimated to 
be 18% for the prostate D90 when T2 and T1 weighted MR 
images were used. This figure was increased to 23% when the 
delineation was done on CT images. 
Functional MR imaging, such as dynamic-enhanced MR, 
diffusion weighted imaging and MR spectroscopy, gives the 
opportunity to image microenvironmental characteristics of a 
tumour. Specific areas within the target volume with a high 
burden of disease or with biological characteristics indicating 
radioresistance may be targeted for higher dose delivery. 
Even though MR imaging is excellent for target delineation, 
localisation of the applicators (i.e. the source path) or the 
seeds could be challenging. Some applicators (e.g. steel 
applicators or shielded applicators) are not even MR 
compatible. In general it is easier to visualise the applicator 
and source(s) in CT images. For rigid MR compatible 
applicators (e.g. plastic tandem-ring-applicator) so called 
library applicator files could be used. Then applicator file, 
including information about the applicator surface 
dimensions and the source path, can be imported into the MR 
images and rotated and translated until it matches the 
images. In some situations the needle tip could be difficult to 
localise in MR images. Then supplementary imaging could be 
used (e.g. CT) and image registration should be performed 
with the aim of matching the applicator geometry and not 
the bony anatomy. The dosimetric consequences of 
uncertainties in the applicator localisation are smaller 
compared to consequences of uncertainties in the target 
delineation. For the HR CTV D90 an average of 2% change per 
mm displacement of a ring applicator has been found in all 
directions.  
Transrectal US (TRUS) is extensively used in prostate 
brachytherapy and gives an excellent view of the prostate 
gland. However, the presence of needles will preclude the 
image quality. Additionally, localisation of the needle tip 
could be challenging during needle reconstruction. 
TRUS-based brachytherapy procedure offer a method for 
interactive treatment planning and, thus, short time between 
imaging and treatment delivery. Several groups have 
developed methods for “in treatment room” imaging with 
both CT and MR. However, for the latter method, challenges 
due to non MR compatible equipment is substantial. 
   
SP-0034   
Importance of treatment delivery verification 
N . Tselis1 
1Klinikum Offenbach GmbH, Radiation Oncology, Offenbach, 
Germany 
 
Abstract not received. 
 
OC-0035   
Catheter displacement and dosimetry for single fraction 
MRI guided focal prostate HDR brachytherapy 
M. Maenhout1, J.R.N. Van der Voort van Zyp1, M. Peters1, M. 
Van Vulpen1, M.A. Moerland1 
1UMC Utrecht, Department of Radiation Oncology, Utrecht, 
The Netherlands  
 
Purpose/Objective: The aim of this study is to analyze the 
effect of catheter displacement and anatomical variations 
(prostate and organs at risk) on the dose distribution in MRI 
guided single fraction high dose rate (HDR) focal 
brachytherapy of the prostate. 
Materials and Methods: Twenty-two patients were treated 
with MRI guided focal HDR brachytherapy (Iridium-192) in a 
single fraction of 19 Gy. A multiparametric MRI was used to 
define the tumor region and was matched with the 
intraoperative ultrasound (US). For the treatment, self-
anchoring umbrella catheters were used (1). For dose 
3rd ESTRO Forum 2015                                                                                                                                         S17 
 
planning purposes, a 1.5T MRI was made directly after US 
guided catheter placement. Two sets of 3D MR images were 
acquired using balanced steady state free precession 
sequences with fat suppression; SPIR (spectral presaturation 
with inversion recovery) in sagittal and SPAIR (spectral 
attenuated inversion recovery) in transverse direction. These 
planning scans were used for catheter reconstruction and 
generation of the intra-operative HDR brachytherapy plan 
(Figure 1a,b). After treatment (before removal of catheters), 
a second MRI was performed. Regions of interest were also 
delineated on the post-treatment MRI scan and the catheters 
of 6 patients were reconstructed . The displacement of 
catheters between the MRI scans were analyzed. The intra-
operative dose plan was applied to the post-operative MRI 
scan to assess the influence of catheter migration and 
anatomical variation on the dose delivered to the target and 
the organs at risk. 
Figure 1. A: sagital SPIR image, B: transveral SPAIR image, C-
F: dose differences in CTV and organs at risk between intra-
operative (Intra-op) and post-operative plan (Post-op) 
 
 
Results: In total, the displacements of 87 catheters were 
investigated in the x,y and z direction (Table 1). A 
displacement of 4-5 mm was seen in the z-direction of 2 
catheters. In most catheters, a migration of only 0-2 mm was 
observed. The differences in DVH parameters between the 
intra-operative plan and the post treatment plan are small 
(Figure 1c-f). Intra-operative and post treatment coverage of 
the CTV are comparable (Figure 1c) and dose constraints for 
the organs at risk (D10% urethra 21 Gy, D1cc bladder and 
rectum 12 Gy) were met for almost all cases (Figure 1d-f). 
The D1cc rectum and D1cc bladder were slightly exceeded in 
two cases. In two patients (no. 4 and 6) the D95 of the CTV 
was reduced to prevent large violations in the constraints for 
the organs at risk. 
Table 1: catheter shifts during treatment, post treatment MR 
compared to per operative MR.  
 
 
Conclusions: There is minimal displacement of catheters 
during a single fraction focal MRI guided HDR brachytherapy. 
The differences in dose to the CTV and the organs at risk 
between the intra-operative and post treatment plans are 
small and seem clinically irrelevant. Preliminary results in 
this study show that the intra-operatively planned dose 
resembles the actual delivered dose. 
(1). Pieters BR et al, Radiother Oncol. 2006 Jul;80(1):69-72. 
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Purpose/Objective: In our department, HDR brachytherapy 
as a monotherapy is performed in 4 fractions of 9.5 Gy within 
36 hours for low and intermediate risk prostate cancer (PCa). 
Although the implanted catheters are fixed in a template, 
displacement of catheters does occur between the fractions. 
A simulation study performed in our department showed a 
substantial influence of implant displacement >3 mm on 
organ at risk constraints and target coverage. Therefore, 
displacements >3 mm were corrected. 
We investigated the influence of correction of displaced 
implanted catheters on acute and late toxicity in prostate 
cancer treated by HDR brachytherapy. 
Materials and Methods: Between 2007 and 2013 158 PCa 
patients treated with HDR monotherapy were included. 
The implant displacement was assessed before each fraction 
for every patient according to a set-up protocol using a 
lateral X-ray to check the position of the catheter tips 
relative to the implanted markers. Displacements ≤3 mm 
were not corrected. 
The cumulative gastrointestinal (GI) and genitourinary (GU) 
acute and late toxicities were assessed using both the clinical 
record forms and the self-assessment patients questionnaires. 
Toxicity occurring within 100 days was defined as acute and 
after 100 days as late. 
Significance of difference in acute toxicity between the two 
groups (with and without displacement) was tested using 
Pearson's chi-squared test. Cox regression analysis was 
applied to compare the incidence rate of late toxicity. 
Results: Implant displacement was reported in 72 patients 
(DP). 57 (80%) DP shows one displacement during the 
treatment course, 15 DP (20%) showed more than one 
displacement. DP were divided into 3 groups: implant 
displacement ≤3 mm (4 patients, 5.7%), >3-5 mm (44 patients 
, 61%), >5mm (24 patients, 33.3%). No displacements were 
seen in 86 patients (NDP). 
Acute grade ≥2 GI toxicity was reported in 25.6% NDP and 
30.6% DP (p=0.49). Acute GU toxicity was reported in 36% 
NDP and 44.4% DP (p=0.28).  
